Affiblot: Semi-quantitative Selection and Characterization of Research Antibodies

0545733 - ÚIACH 2022 US eng A - Abstrakt
Svobodová, Z. - Novotný, Jakub - Ospálková, B. - Nemčeková, K. - Tripská, K. - Foret, František - Bílková, Z.
Affiblot: Semi-quantitative Selection and Characterization of Research Antibodies.
MSB 2021 Final Program. 2021.
[International Symposium on Microscale Separations and Bioanalysis /37./. 12.07.2021-15.07.2021, Boston]
Grant ostatní: AV ČR MSM200312001
Program: Program na podporu mezinárodní spolupráce začínajících výzkumných pracovníků
Institucionální podpora: RVO:68081715
Klíčová slova: binding reagents * rubella * validation
Obor OECD: Analytical chemistry
https://msb-conferences.org/detailed-program/

The affiblot is a dot blot-based palm-sized device that researchers, laboratories, and institutions can use to semi-quantitatively evaluate and select the most suitable antibody among different suppliers that fit their application in terms of affinity comparison, cross-reactivity, and batch-to-batch variability. The device is also able to control the condition of the antibodies for the duration of their storage. Moreover, this simple, fast, and flexible technique does not require special equipment, except a vacuum pump and camera. If more precise results are required, the ChemiDoc imaging system can be used instead of the camera. The target can be a purified or recombinant peptide, protein, or whole bacterial cell. This device could be used to compare any antibodies or affinity reagents that have not yet been on the market for a long time and are therefore not yet thoroughly validated, such as anti-SARS-CoV2 antibodies. These antibodies are currently widely used to reveal the mechanisms of virus replication and host-to-host transmission, the development of diagnostic methods, and clinical research. The dot blot-based device could help researchers rapidly select the most suitable and functional antibody for their application. Therefore, our future intent will include the evaluation of several anti-SARS-CoV-2 antibodies for research use.
Trvalý link: http://hdl.handle.net/11104/0322393